Skip to main content

Table 4 The detection rates of precancerous lesions or cancer in HPV-positive women

From: Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study

  HPV testing with genotyping triage HPV testing with cytology triage
HPV-16/18 Non-16-18 HPV genotypes
Women who attended immediate colposcopy adherence to the protocola
 CIN2+, n/N (%) 1922/13 488 (17.3) 902/7167 (13.8) 870/4127 (24.1)
  aOR (95% CI) 1.32 (1.22–1.43) Ref (1.00) 1.96 (1.77–2.16)
  Colposcopies per CIN2+ detection 5.8 7.2 4.1
 CIN2 or 3, n/N (%) 1736/13 488 (15.6) 861/7167 (13.1) 785/4127 (21.8)
  aOR (95% CI) 1.24 (1.14–1.34) Ref (1.00) 1.82 (1.64–2.01)
 ICC, n/N (%) 186/13 488 (1.7) 41/7167 (0.6) 85/4127 (2.4)
  aOR (95% CI) 2.75 (2.00–3.78) Ref (1.00) 3.64 (2.55–5.20)
Women who needed intensified screening but attended immediate colposcopy b
 CIN2+, n/N (%) NA 102/3507 (2.9) 83/1673 (5.0)
  aOR (95% CI) NA Ref (1.00) 1.92 (1.38–2.67)
  Colposcopies per CIN2+ detection NA 34.5 20.0
 CIN2 or 3, n/N (%) NA 91/3507 (2.6) 67/1673 (4.0)
  aOR (95% CI) NA Ref (1.00) 1.68 (1.18–2.39)
 ICC, n/N (%) NA 11/3507 (0.3) 16/1673 (1.0)
  aOR (95% CI) NA Ref (1.00) 3.94 (1.61–9.63)
  1. Note: HPV human papillomavirus, aOR adjusted odds ratio, CI confidential interval, CIN2+ cervical intraepithelial neoplasia 2 grade or worse, ICC invasive cervical cancer, Ref reference, NA not applicable. aThese women included those who were HPV-16 or HPV-18 positive, non-16-18 high-risk HPV positive with abnormal cytology, and any HPV positive with abnormal cytology. bThese women included those who were non-16-18 high-risk HPV positive with negative cytology and any HPV positive with negative cytology. aOR was calculated by using multivariate logistic regression adjusted for age, ever screening, and income classification